Novanta (NOVT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
The annual meeting will be held virtually on May 28, 2026, with shareholders able to vote and ask questions online.
Key proposals include electing nine directors, an advisory vote on executive compensation, and appointing Deloitte & Touche LLP as auditor.
The Board recommends voting in favor of all proposals and emphasizes the importance of shareholder participation.
Voting matters and shareholder proposals
Shareholders will vote on the election of nine directors, approval of executive compensation (say-on-pay), and the appointment of Deloitte & Touche LLP as auditor.
Cumulative voting is permitted for director elections, and a majority of votes cast is required for approval.
Shareholders may submit proposals for the 2027 meeting by December 30, 2026, and director nominations by January 24, 2027.
Board of directors and corporate governance
The Board consists of nine directors, eight of whom are independent; the Chair and CEO roles are combined.
Board committees include Audit, Compensation, ESG, and Transaction Committees, all chaired by independent directors.
The ESG Committee oversees board nominations, governance, sustainability, and cybersecurity.
Annual board and committee self-evaluations are conducted, and director tenure and age limits are in place.
Latest events from Novanta
- Q2 2026 saw 10.3% revenue growth, strong cash flow, and raised outlook after Riverpoint deal.NOVT
Q2 2026 - Acquisition doubles recurring revenue, delivers $80M+ synergies, and closes Q3 2026.NOVT
M&A announcement - Fourfold revenue growth driven by innovation in medical and automation markets.NOVT
Investor presentation - Medical and robotics focus drives recurring revenue and double-digit growth through innovation and M&A.NOVT
46th Annual William Blair Growth Stock Conference - Directors, executive pay, and auditor were approved; no shareholder questions were raised.NOVT
AGM 2026 - Q1 2026 revenue up 10.4%, bookings up 37%, and cash flow surged, with strong 2026 outlook.NOVT
Q1 2026 - Record revenue, strong bookings, and 2026 guidance project further growth and margin expansion.NOVT
Q4 2025 - Q2 revenue up 2.8% to $236M, with medical growth offsetting weak industrial demand.NOVT
Q2 2024 - Q3 2024 revenue up 10.3% to $244.4M, with acquisitions driving growth and flat organic sales.NOVT
Q3 2024